<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35913017</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>5-6</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>ALSUntangled #66: antimycobacterial antibiotics.</ArticleTitle><Pagination><StartPage>539</StartPage><EndPage>543</EndPage><MedlinePgn>539-543</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2022.2104650</ELocationID><Abstract><AbstractText>Several infections have been associated with motor neuron diseases resembling ALS, including species of viruses, bacteria, and parasites. <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> (MAP), most known for its probable etiologic association with Crohn's disease, has been suggested as another possible infectious cause of motor neuron disease. Two published case reports describe the successful treatment of ALS-like symptoms with antimycobacterial antibiotics. Both cases had atypical features. Based on these, we believe it would be reasonable to begin performing chest imaging in PALS who have features of their history or exam that are atypical for ALS such as pain, fevers, or eye movement abnormalities. If the chest imaging is abnormal, more specific testing for mycobacteria may be indicated. Until there is more clear evidence of an association between mycobacteria and ALS, we cannot endorse the widespread use of potentially toxic antimycobacterial antibiotics for PALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pierce</LastName><ForeName>Ellen S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0003-2045-191X</Identifier><AffiliationInfo><Affiliation>Spokane Valley, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkhaus</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beauchamp</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UNC Neurosciences Clinical Trials Unit, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bromberg</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Utah, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Gregory T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goslinga</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greeley</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Northwest Neurological Associates, PLLC, Spokane, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kihuwa-Mani</LastName><ForeName>Sky</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Undergraduate, UNC-Greensboro, Greensboro, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levitsky</LastName><ForeName>Gleb</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Real Health Clinic, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lund</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Undergraduate, Green Hope High School, Cary, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1269-9053</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, University of Sheffield, Sheffield, South Yorkshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pattee</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierce</LastName><ForeName>Kaitlyn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polak</LastName><ForeName>Meraida</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Emory, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratner</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Undergraduate, Longmeadow High School, Longmeadow, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wicks</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2293-9284</Identifier><AffiliationInfo><Affiliation>Independent Consultant, Lichfield, England, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedlack</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016927" MajorTopicYN="Y">Mycobacterium avium subsp. paratuberculosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">antimycobacterial antibiotic therapy</Keyword><Keyword MajorTopicYN="N">infectious ALS</Keyword><Keyword MajorTopicYN="N">motor neurone disease</Keyword><Keyword MajorTopicYN="N">paratuberculosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>1</Day><Hour>7</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35913017</ArticleId><ArticleId IdType="doi">10.1080/21678421.2022.2104650</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>